Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Drug Safety Plan Expected Within Two Weeks, Outgoing HHS Secretary Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The Administration will present a plan designed to "improve the conditions" at FDA by Dec. 17, HHS Secretary Thompson says while announcing his resignation. Thompson cites need for an "independent office of safety to look at drugs."

You may also be interested in...



FDA Drug Safety Initiative Will Include New Website On Rx Risks

The site is intended as an avenue for the agency to disclose safety issues that have not yet been definitively reviewed, and to emphasize the risks with all prescription drugs. The website proposal is understood to be in the internal agency review phase.

FDA Drug Safety Initiative Will Include New Website On Rx Risks

The site is intended as an avenue for the agency to disclose safety issues that have not yet been definitively reviewed, and to emphasize the risks with all prescription drugs. The website proposal is understood to be in the internal agency review phase.

Rx Import Report: Task Force May Miss Dec. 8 Deadline

CMS Administrator McClellan says the drug import task force, of which he is a member, will publish its report “as close to the deadline as possible.” The Dec. 8 deadline for delivering the report to Congress is mandated under the Medicare Modernization Act.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132028

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel